Topics

"Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL" Drugs and Medication Database

05:50 EST 29th January 2020 | BioPortfolio

Here are the most relevant "Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL" Drugs and Medications that we have found in our database.

More Information about "Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL" on BioPortfolio

We have published hundreds of Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL news stories on BioPortfolio along with dozens of Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Clinical Trials and PubMed Articles about Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Companies in our database. You can also find out about relevant Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Drugs and Medications on this site too.

Showing "Phase Study Assess Safety Preliminary Efficacy Tafasitamab Tafasitamab" Drugs and Medications, all 4

Possibly Relevant

Hexalen [eisai inc.]

Hexalen

Iclusig [millennium pharmaceuticals, inc.]

These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG(ponatinib) tablets, for oral use Initial U.S. Approval: 2012

Venclexta [abbvie inc.]

These highlights do not include all the information needed to use VENCLEXTA safely and effectively. See full prescribing information for VENCLEXTA. VENCLEXTA (venetoclax tablets) for oral use Initial U.S. Approval: 2016

Sprycel [e.r. squibb & sons, l.l.c.]

These highlights do not include all the information needed to use SPRYCEL safely and effectively. See full prescribing information for SPRYCEL. SPRYCEL (dasatinib) tablets, for oral useInitial U.S. Approval: 2006



Quick Search